The FDA has approved Cresilon’s Traumagel, a hemostatic gel capable of halting bleeding from gunshot wounds in seconds. With its unique algae and fungi-based formula, Traumagel promises to revolutionize emergency medical care by providing a swift and efficient solution to one of medicine’s age-old challenges: rapid blood loss control.
Initially proven in over 10,000 veterinary clinics under the name Vetigel, this innovative gel has been pivotal in saving countless animal lives during surgeries and emergency situations. Now, with FDA clearance, Traumagel is set to make its debut in human medicine later this year. Cresilon’s founder, Joe Landolina, highlights that the gel’s “flowable” properties not only prevent bleeding swiftly but also enhance the safety and ease of treating complex wounds such as those from bullets.
“Traditional methods require packing gauze into wounds, which can be painful and risky,” Landolina explains. “Traumagel naturally conforms to the wound’s shape, reducing exposure risks for medical personnel.”
The gel’s potential has caught the attention of the Department of Defense, which is considering its broader applications for battlefield injuries. According to Landolina, “91% of battlefield deaths are due to preventable hemorrhage. Traumagel could significantly reduce these numbers by offering an immediate and effective bleeding control solution.”
Cresilon is already partnering with the Walter Reed Army Institute of Research to explore the gel’s benefits for traumatic brain injuries. Preliminary studies have shown promising outcomes in controlling intracranial pressure, though more research is needed to confirm its effectiveness in humans.
With a large-scale biomanufacturing facility in Brooklyn, Cresilon is gearing up for the product’s release, ensuring that EMTs and physicians nationwide are trained to use Traumagel effectively. Landolina notes that the training process is straightforward, as Traumagel requires less precision compared to Vetigel’s application in varied animal anatomies.
Specialists in emergency medicine are eagerly anticipating Traumagel’s market introduction, predicting it will become a staple in trauma care. Dr. Sarah Mendelson, an ER specialist, states, “This could be a transformative tool in emergency departments and even in field operations, significantly impacting patient outcomes.”
As Traumagel prepares to enter the public domain, its influence on both civilian and military medical practices is poised to redefine how severe bleeding is managed, offering hope for countless lives in emergency scenarios. The implications of this development are vast, promising a new era in immediate trauma care and beyond.
